Previous Close | 7.37 |
Open | 7.50 |
Bid | 7.33 x 1000 |
Ask | 7.50 x 1200 |
Day's Range | 7.36 - 7.70 |
52 Week Range | 3.26 - 11.35 |
Volume | 424,379 |
Avg. Volume | 315,112 |
Market Cap | 308.991M |
Beta (5Y Monthly) | 1.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.80 |
Earnings Date | Nov 12, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.00 |
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Depositary Shares (ADSs) of the Company, at a price to the public of $7.84 per ADS. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company.
The decline came after the specialty biopharmaceutical company announced that it was increasing the size of its previously announced public stock offering. RedHill now plans to offer nearly 3.2 million American depositary shares (ADSs) at a price of $7.84 per share. There's good news and bad news with RedHill's decision to increase the size of its public stock offering.
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,188,776 American Depositary Shares (ADSs) of the Company, at a price to the public of $7.84 per ADS, less underwriting discounts and commissions. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. The closing of the offering is expected to occur on or about January 14, 2021, subject to satisfaction of customary closing conditions.